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Introduction. Most of the kidney masses are being detected incidentally with smaller size due to widespread use of imaging
modalities leading to increased RCC incidence worldwide with an earlier stage. This article reviews the role of open partial
nephrectomy (PN) in the management of small renal masses. Material and Methods. Review of the English literature using
MEDLINE has been performed between 1963–2008 on small renal masses, partial nephrectomy, kidney cancer, nephron sparing
surgery(NSS),radicalnephrectomy,laparoscopy,andsurgicalmanagement.SpecialemphasiswasgivenontheindicationsofNSS,
oncological outcomes and comparison with open and laparoscopic PN. Results. Overall 68 articles including 31 review papers, 35
human clinical papers, 1 book chapter, and 1 animal research study were selected for the purpose of this article and were reviewed
by the authors. Conclusions. Currently, open NSS still remains as the gold standard surgical treatment modality in patients with
small renal masses.
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1. INTRODUCTION
Renal cell carcinoma (RCC) accounts for 3% of adult
solid tumors; and the highest incidence of RCC is detected
between 50–70 years of age [1, 2]. Almost 20,000 renal
cancer patients are estimated to be detected yearly in the
European Union [3]. In the pathogenesis of conventional
RCC, mutations leading to inactivation of the von Hippel
Lindau (VHL) tumor suppressor gene have been detected
in the hereditary and up to 80% of sporadic forms of clear
cell RCC. Premalignant lesions in the kidney such as renal
intraepithelial neoplasia have been described, which seems
to be sharing similar genetical changes with RCC [4, 5].
Independent predictors of survival in patients with RCC are
limited. Tumor stage, grade, and patient-performance status
are the known prognostic indicators [6].
Currently, most of the kidney masses are being detected
incidentally up to 40% with smaller size due to widespread
use of imaging modalities such as ultrasound (US), com-
puted tomography (CT), and magnetic resonance imaging
(MRI). This leads to increased RCC incidence worldwide [7]
with an earlier stage which can be cured by surgery [8].
This paper reviews the role of open partial nephrectomy
(PN) in the management of small renal masses particularly
focusing on indications, oncological outcomes and compar-
ison with laparoscopic PN.
2. MATERIALS AND METHODS
Review of the English literature using MEDLINE has been
performed between 1963–2008 on small renal masses, par-
tial nephrectomy, kidney cancer, nephron sparing surgery,
radical nephrectomy, indications, outcomes, surgical man-
agement, and laparoscopy.
Overall 68 articles including 31 review papers, 35 human
clinical papers, 1-book chapter, and 1 animal research study
were selected for the purpose of this article and were
reviewed by the authors.
3. RESULTS AND DISCUSSION
Small renal masses are considered as tumors less than 4cm
in size in the kidney although there is not an established
consensus concerning a clear cut-oﬀ value for the deﬁnition2 Advances in Urology
ofa“smallrenalmass.”However,although4cmiscommonly
considered as the size limit for nephron sparing surgery
(NSS) in kidney tumors, when technically feasible, partial
nephrectomy (PN) should be performed irrespective of
tumor size [9].
3.1. Radicalnephrectomyversuspartialnephrectomy
Radical nephrectomy (RN) was ﬁrst described by Robson in
1963; it has been the standard for the surgical treatment of
kidney cancer [10]. Traditionally, RN can be regarded as the
optimal technique with long-term cancer control in kidney
cancer [11]. Five-year cancer speciﬁc survival for patients
with organ-conﬁned disease is over 90% after surgery alone.
Since 15–25% of incidentally detected tumours are benign,
removing the whole kidney for a small benign lesion is
not logical [12]. Current indications of open RN can be
summarized as large tumor size which is not suitable for
NSS or for laparoscopy, locally advanced diseases, existence
of complicated tumor thrombus with vena cava extension,
and presence of other concomitant diseases such as renal
artery stenosis or single-organ metastases necessitating open
surgery [13]. Due to improved technology regarding radi-
ologic imaging modalities and their frequent use, currently
most of the kidney tumors are detected incidentally with
smaller tumor size and are associated with less lymph node
and adrenal gland involvement [14]. Therefore, there is a
tendency to perform NSS rather than RN in suitable kidney
tumors particularly with recent improvements in surgical
techniques.
PN was ﬁrst performed by Czerny in 1887 [15]a n d
Vermooten described indications of conservative surgery in
kidney tumors in 1950 [16]. The goal of NSS is to preserve as
much normal renal parenchyma as possible and meticulous
cancer control with negative surgical margins and no local
recurrence in the follow-up [17]. Multiple studies in the last
decade have established the safety and eﬃcacy of PN for
selected cases with small renal tumors [11, 18, 19]. Such
considerations have led to expanding the indications of PN
to include centrally located tumors and larger tumors up to
7cm[18, 19].
3.2. Indicationsofopenpartialnephrectomy
The TNM 1997 classiﬁcation considers tumor size of 4cm
as cut-oﬀ value in order to classify stage T1 tumors as
T1a (≤4cm) and T1b (4–7cm) [20]. Excellent outcomes
regarding tumors less than 4cm in size treated with NSS
have an important impact in this staging. Current indica-
tions for open PN are summarized on Table 1. In elective
setting when contralateral kidney is normal, NSS should be
attempted whenever feasible irrespective of the status of the
contralateral kidney.
3.3. Surgicaltechniqueandcomplications
We prefer a ﬂank incision and a lumbar extraperitoneal
approach. Kidney is mobilized completely and explored
for satellite lesions. If necessary, intraoperative ultrasound
Table 1:Openpartialnephrectomyindications(tableadaptedfrom
12).
I. AbsoluteIndications
a. Tumors in a solitary kidney
b. Bilateral synchronous renal masses
c. Severe renal insuﬃciency
II.Relative Indications
a. Presence of pre-existing renal disease in the contralateral
kidney
1. Nephrolithiasis
2. Recurrent pyelonephritis
3. Mild-moderate renal insuﬃciency
4. Ureteropelvic junction obstruction
5. Vesicoureteral reﬂux
b. Presence of diseases predisposing to renal insuﬃciency
1. Diabetes
2. Hypertension
c. Patients with known multifocal disease or underlying genetic
syndromes
1. Papillary RCC
2. Von Hippel-Lindau disease
can be used. Renal vessels are controlled by using vascular
clamps, vascular tape, or by the surgeon’s ﬁngers. In diﬃcult
cases the artery and the vein are clamped, and ice slush
should be applied in order to cool down the kidney. Scalpel,
laser,ultrasonicaspirator,waterjet,cautery,bluntdissection,
or combinations of these can be used to cut the renal
parenchyma in order to remove the tumor with surrounding
few millimeters of healthy parenchyma and together with the
covering perirenal fat. In case of any suspicion in terms of
surgical margins, further resection can be performed. Frozen
section examination of the tumor bed is usually not helpful.
Bleeders are coagulated or sutured and collecting system is
closed by absorbable sutures in a water-tight manner if it
has been opened. Peroperative hydration and diuresis by
mannitol infusion are very helpful. Absorbable sutures for
approximationoftherenalparenchymaina“sutureofeight”
or “Z” sutures fashion are useful. Perirenal fat or omentum
can be used in order to close the defect. A drain is placed
in the retroperitoneum and wound is closed. Because tumor
cells might remain in the residual kidney after resection,
enucleation is usually discouraged (Figure 1)[ 21].
Renal failure, post operative hemorrhage, urine leak, and
urinary ﬁstula are the most frequently seen complications
afteropenNSS[21,22].Recently,VanPoppeletal.compared
the complications of elective open NSS surgery and RN
for low-stage, incidentally detected, solitary, small (≤5cm)
RCCs in a prospective study in the presence of a normal
contralateral kidney (Table 2). They concluded that NSS can
be performed safely in this patient group with slightly higher
complication rates than after RN [23].Z. Kirkali and A. Erdem Canda 3
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Figure 1:TechniquesusedinopenNSS.NSS:Nephronsparingsur-
gery.
Table 2: Complications of open NSS and RN [23].
NSS (%),
(n = 268)
RN (%),
(n = 273)
Rate of severe haemorrhage 3.1 1.2
Pleural damage 11.5 9.3
Spleen damage 0.4 0.4
Postoperative CT abnormalities 5.8 2.0
Urinary ﬁstula development 4.4 —
Reoperation for complications 4.4 2.4
Perioperative blood loss was slightly higher after RN (P>. 05).
NSS: Nephron sparing surgery, RN: Radical nephrectomy, CT: Computed
tomography.
3.4. Outcomesofopenpartialnephrectomy
Similar cancer-speciﬁc survival rates and oncologic out-
comes have been detected in patients with small (<4cm)
renal masses who underwent RN or NSS. Therefore, cur-
rently NSS is considered as the treatment of choice in these
patients (T1a tumors) [9, 24–29]( Table 3).
Ten-year oncological and functional follow-up data
revealed almost 100% survival, especially in patients with
renal tumors less than 4cm in size [34–38]w i t hP N .T h e r e -
fore, open NSS is currently accepted as the gold standard
treatment modality for patients with small, exophytic, easily
resectable renal masses [19, 34]. In a series of 435 patients
who underwent NSS for a tumor size between 2.6–4.0cm,
local recurrence was detected in 3 patients (0.7%) with a
mean follow-up of 31–76 months, which is ten times lower
than the rate for NSS performed for an absolute indication
[39]. Local recurrence has been reported to be between 0–
12% in NSS which is related with multifocal disease or
insuﬃcient resection of the tumor [40]. Local recurrence is
expected to be more frequent locally advanced disease [41].
Presence of preneoplastic lesions such as renal intraep-
ithelial neoplasia in the residual kidney might be a factor for
the occurrence of local recurrence [4]. However, recurrence
due to insuﬃcient resection could be prevented by proper
surgical technique [42]. Multifocal tumors can be detected
both in large- and small-sized tumors [4]. Although there is
a possibility of presence of multifocality and premalignant
lesions,localrecurrencerateisquitelowinwellselectedcases
after NSS [43].
3.5. Preoperativekidneybiopsy
It has been demonstrated that almost a quarter of all small
renal masses (<4cm) are benign lesions like angiomyoli-
poma, oncocytoma, or metanephric adenoma. Preoperative
diagnosisoftheselesionsisdiﬃcultdespitelatestadvancesin
imaging techniques [27, 40, 44, 45]. Therefore, performing
RN would be unnecessary for these benign lesions. One may
possibly think of diagnosing these lesions preoperatively by
kidney biopsy. Currently, the role of renal biopsy in diagnos-
ing these lesions is controversial. Although preoperative ﬁne
needle aspiration biopsy can be performed for diagnosis, its
sensitivity is low, has complication risks such as bleeding and
tumor seeding, might give false positive and false negative
results, and ﬁnally it needs an experienced cytopathologist
particularly subspecialized in kidney and RCC [17, 46]. We
suggest kidney biopsy particularly in those patients where
renal lymphoma or metastatic involvement of the kidney is
suspected [47].
3.6. OptimalmarginsinopenNSSandsigniﬁcanceof
performingtumorbedbiopsies
For tumors smaller than 4cm, the local/ipsilateral renal
recurrence rate has been reported to range between 1.5 and
4% in open NSS series [34, 36]. In the past, a 1cm normal
parenchyma was suggested as a safety margin in NSS but
controversyexistsconcerningtheoptimalmarginwidth[48].
Intraoperative biopsy and frozen-section examination of the
tumor bed is suggested in order to rule out residual tumor
in the kidney [49]. However, false-positive and false-negative
results can be obtained due to freezing artifacts and diﬃculty
in distinguishing cancer cells from normal cells [50]w h i c h
might also lead to unnecessary resections or even RN [51]. It
has been shown that more than 30% of small renal tumors
(≤4cm) did not have an intact pseudocapsule; and cancer
cells might be detected beyond the pseudocapsule reaching
up to 0–5mm [52] therefore, an amount of normal kidney
tissue surrounding the tumor is suggested to be included
with PN in order to prevent incomplete resection [53]. This
amount has been recommended to be at least 5mm in NSS
by some authors [52], whereas others suggest a normal tissue
safety margin of ≥1mmtoberemoved[54]. In conclusion,
the margin status rather than size seems to be important in
NSS and 1mm of normal parenchyma around the tumor
s e e m st ob ee n o u g h .
It is known that RCC has a 1–5% recurrence rate
in the contralateral kidney particularly in surgical margin
positive patients and patients with multifocal tumors which
support NSS in this patient group [55, 56]. Several authors
suggest intraoperative use of ultrasonography to rule out
multifocal disease, and to clearly deﬁne tumor extent [57,
58]. Coagulation of the tumor bed in addition to biopsies
is recommended when tumor enucleation is performed [59].4 Advances in Urology
Table 3: Selected published series including patients who underwent open NSS or RN for renal masses due to their tumor size (table
modiﬁed from [14]).
Author Reference Year N Local recurrence (%) 5-year dfs (mos)
Tumor size <4cm in size∗
Hafez et al. [26] 1999 310 0.6 96
Lee et al. [27] 2000 79 0 100
McKiernan et al. [24] 2002 117 1.2 100
Patard et al. [18] 2004 314 0.8 98
Tumor size >4cm in size∗∗
Hafez et al. [26] 1999 175 0.8 86
Patard et al. [18] 2004 65 3.6 94
Leibovich et al. [28] 2004 91 5.4 98
Becker et al. [29] 2006 69 5.8 100
Selected series comparing outcomes of patients underwent NSS or RN for renal masses∗
RN NSS RN NSS RN NSS
Patard et al. [18] 2004 1075 379 99 99 97 98
Lee et al. [27] 2000 183 79 100 100 96 96
Leibovich et al. [28] 2004 841 91 98 95 86 98
McKiernan et al. [24] 2002 173 117 99 96 100 100
∗Median follow-up is >25 months for all studies.
∗∗Median follow-up is >47 months for all studies.
N: Number of patients, dfs: disease-free survival, FU: Follow-up, mos: months.
Table 4: Comparison of laparoscopic versus open PN in patients with a solitary renal tumor of 7cm or less in size (table modiﬁed from
[30]).
Laparoscopic PN (n = 100) Open PN (n = 100) P
Complications:
Major intraoperative 5% 0% .02
Renal/urological 11% 2% .01
Median surgical time (hours) 33 . 9 <.001
Blood loss (mL) 125 250 <.001
Mean warm ischemia time (minutes) 27.8 7.5 <.001
Median analgesic requirement (morphine sulfate
equivalents, mg)
20.2 252.5 <.001
Hospital stay (days) 25 <.001
Average convalescence (weeks) 46 <.001
Median preoperative serum creatinine (mg/dL) 1.0 1.0 .52
Median postoperative serum creatinine (mg/dL) 1.1 1.2 .65
PN: Partial nephrectomy.
3.7. Openversuslaparoscopicpartialnephrectomy
In the recent years, laparoscopy has gained popularity and
emerged as an alternative to open PN in the treatment
o fr e n a lm a s s e s[ 58]. Technical advances have enabled
laparoscopists to duplicate the techniques used during open
PN, including vascular control, hemostasis, and repair of the
pelvicalyceal system [58, 60]. Promising postoperative and
intermediate-term oncological outcomes have been reported
with laparoscopic partial nephrectomy (LPN) [57, 61, 62].
Recently, Lane BR and Gill IS reported their 5-year
outcomes in LPN including 58 patients which are com-
parable to those of open NSS. At a median follow-up
of 5.7 years, no distant recurrence and a single local
recurrence (2.7%) were detected. Overall and cancer-speciﬁc
survival was 86% and 100%, respectively, at 5 years [62].
Moinzadeh et al. also reported oncological results in 100
patients with a minimum follow-up of 3 years. Overall
survival was 86%, and a cancer-speciﬁc survival was 100%
[61].
Although LPN seems to be a promising and attractive
surgical approach in the management of renal masses, there
are still some problems for LPN. Bleeding and hemostasis,
prolonged warm ischemia, longer operative time, increasedZ. Kirkali and A. Erdem Canda 5
Table 5: Comparison of selected published series related with LPN. Min: Minutes.
Authors Crepel et al. H¨ a c k e re ta l . H a b e re ta l .
Reference [31][ 32][ 33]
Center Mutlicenter study Elisabethinen hospital Cleveland clinic
France Austria Ohio, USA
Year 2007 2007 2006
Number of patients 91 25 >500
Tumor size (cm) 2.7 2.6 2.9
Route Transperitoneal Transperitoneal Transperitoneal
retroperitoneal retroperitoneal
Warm ischemia time (min) 35 29 32
Mean operating time 163 min 212 min Transperitoneal: 3.5 h
Retroperitoneal: 2.9 h
Complication rate (%) 17.6 8 36 and 16
Mean blood loss (mL) 363 177.4 150 versus 100 and 231
Transfusion rate (%) 6.6 4 Not reported
Hospital stay (days) 9.1 8.3 Transperitoneal: 2.9
Retroperitoneal: 2.2
LPN: Laparoscopic partial nephrectomy.
intraoperative and renal/urological major complication rates
are considered as current problems associated with LPN.
Hemostasis and ischemia time is the most challenging steps
in LPN [60]. Bleeding during LPN is an important problem
for the surgeon although improved surgical techniques and
skills together with the use of new hemostatic sealants such
as ﬁbrin glue-coated collagen patch which contains purely
human coagulation factor components can be helpful in
o r d e rt oo v e r c o m et h i sp r o b l e m[ 63–65].
There are several studies investigating the impact of the
warm ischemia time on renal functions and as a widely
accepted guideline for clinical practice, warm renal ischemia
period exceeding 30 minutes is not recommended [66].
Furthermore, it is technically very demanding and time
consuming to produce cold ischemia during laparoscopic
surgery [66]. Preservation of maximum functional kidney
tissue is one of the goals in PN, however, longer warm
ischemia times have been reported with LPN [33]c o m p a r e d
to open NSS [30, 37].
T h eo p e r a t i n gt i m es e e m st ob ed e c r e a s e df o rL P Ni nt h e
most experienced centers [30] however the learning curve is
not short and technical feasibility of an operation does not
always necessarily mean that it can be performed in common
practice. This is still a major issue when health care costs to
society are concerned [12].
Signiﬁcantly increased major complication rates have
been reported with LPN compared to open NSS by expe-
rienced authors [30, 37, 67]. However, for peripherally
located, small, and exophytic renal masses, we expect these
c o m p l i c a t i o n st ob el o w e r .
The risk of tumor spillage is also a theoretical problem in
LPN [60]. However, tumor spillage has been reported at port
sites in patients undergoing laparoscopic nephrectomy and
nephroureterectomy due to tumor [68].
Decreasedanalgesicrequirement,decreasedhospitalstay,
shortened convalescence, and improved cosmetics are con-
sidered as the main advantages of LPN. The length of stay for
patientsundergoingLPNinlargeseriesfromEurope[31,32]
is ranging from 6 to 9 days whereas the average length of stay
in the United States is between 2 and 4 days [30, 33]. Gill et
al. reported their results comparing open versus laparoscopic
PN (Table 4)[ 30]. Characteristics of some selected series of
LPN are summarized on Table 5 [31–33].
The follow-up after LPN is shorter compared to open
NSS concerning oncologic outcomes. LPN has a long
learning curve and requires high-level laparoscopic skills and
experience. Long-term data indicate that NSS is safe and
oncologically eﬀective in small renal masses <4cminsize.
Until the problems with LPN are overcome, high complica-
tion rates are lowered and longer oncological follow-up data
areavailable,openNSSwillbethestandardtreatmentforthe
surgical management of kidney tumors [12].
4. CONCLUSIONS
Due to widespread use of radiologic imaging modalities,
most of the kidney tumors are being detected incidentally
with smaller size and earlier stage. Similar oncologic out-
c o m e sh a v eb e e nd e t e c t e di np a t i e n t sw i t hs m a l l( <4cm)
renal masses who underwent RN or NSS. Currently, NSS is
considered as the treatment of choice in patients with kidney
tumors when technically feasible irrespective of tumor
size. In last few years laparoscopy has gained popularity
and emerged as an alternative to open PN particularly in
the surgical management of small renal masses. However,
complication rates are higher and oncological follow-updata
is shorter compared to open PN therefore, NSS still remains
as the gold standard surgical treatment modality in patients
with small renal masses.6 Advances in Urology
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